Moderna reports surprise profit, sets out road map for RSV vaccine
By Patrick Wingrove and Leroy Leo (Reuters) -Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and deferred payments, and set out a commercial roadmap for its vaccines in Europe and experimental respiratory syncytial virus (RSV) shot. Shares jumped 8% to $94.65 in early trading, still well off the record high of…